The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
C Neunert, W Lim, M Crowther, A Cohen… - Blood, The Journal …, 2011 - ashpublications.org
Immune thrombocytopenia (ITP) is commonly encountered in clinical practice. In 1996 the
American Society of Hematology published a landmark guidance paper designed to assist …
American Society of Hematology published a landmark guidance paper designed to assist …
Nanocarriers as an emerging platform for cancer therapy
The delivery of drugs through targeted nanocarriers that are internalized by cells provides
an alternative route to diffusion of drugs into cells. Growth factor or vitamin interactions with …
an alternative route to diffusion of drugs into cells. Growth factor or vitamin interactions with …
International consensus report on the investigation and management of primary immune thrombocytopenia
D Provan, R Stasi, AC Newland… - Blood, The Journal …, 2010 - ashpublications.org
Previously published guidelines for the diagnosis and management of primary immune
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …
thrombocytopenia (ITP) require updating largely due to the introduction of new classes of …
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working …
F Rodeghiero, R Stasi, T Gernsheimer… - Blood, The Journal …, 2009 - ashpublications.org
Diagnosis and management of immune thrombocytopenic purpura (ITP) remain largely
dependent on clinical expertise and observations more than on evidence derived from …
dependent on clinical expertise and observations more than on evidence derived from …
Splenectomy for immune thrombocytopenia: down but not out
S Chaturvedi, DM Arnold… - Blood, The Journal of the …, 2018 - ashpublications.org
Splenectomy is an effective therapy for steroid-refractory or dependent immune
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …
thrombocytopenia (ITP). With the advent of medical alternatives such as rituximab and …
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and …
KR Carson, AM Evens, EA Richey… - Blood, The Journal …, 2009 - ashpublications.org
Rituximab improves outcomes for persons with lymphoproliferative disorders and is
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients …
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia
Treatments for immune thrombocytopenic purpura (ITP) providing durable platelet
responses without continued dosing are limited. Whereas complete responses (CRs) to B …
responses without continued dosing are limited. Whereas complete responses (CRs) to B …
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo …
Background Eltrombopag is an oral, non-peptide, thrombopoietin-receptor agonist that
stimulates thrombopoiesis, leading to increased platelet production. This study assessed the …
stimulates thrombopoiesis, leading to increased platelet production. This study assessed the …
CD20 deficiency in humans results in impaired T cell–independent antibody responses
TW Kuijpers, RJ Bende, PA Baars… - The Journal of …, 2010 - Am Soc Clin Investig
CD20 was the first B cell differentiation antigen identified, and CD20-specific mAbs are
commonly used for the treatment of B cell malignancies and autoantibody-mediated …
commonly used for the treatment of B cell malignancies and autoantibody-mediated …